fig3
![DNA damage and metabolic mechanisms of cancer drug resistance](https://image.oaes.cc/f3efe87f-3abe-4ecc-bf0a-499bb69faaa0/4691.fig.3.jpg)
Figure 3. Therapy schematic. Broad-reaching drugs may lend to more durable responses as resistance can arise more rapidly to targeted therapy. Modulating more broad cancer hallmarks - like immune and metabolic targets - may offer smarter drug targets.